Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Post-surgical ctDNA-based molecular residual disease detection in patients with stage I uterine malignancies

In a real-world Signatera series of 101 patients with stage I uterine malignancies, postoperative ctDNA positivity was associated with inferior recurrence-free survival (HR 6.2 at the first time point and HR 15.5 longitudinally) and remained prognostic after adjustment for clinicopathologic risk factors.

Gynecol OncolPubMed 38262240DOI 10.1016/j.ygyno.2023.12.025